// App-Quantinova.ai

56 : AZD0466, a nanomedicine of a potent dual Bcl-2/Bcl-xL inhibitor, exhibits anti-tumor activity in a range of hematological and solid tumor models

Researchers

Presenter

  • Srividya B. Balachander

Principal Investigators

  • Areya Tabatabai

  • Shenghua Wen

  • Francis D. Gibbons

  • Giulia Fabbri

  • Guangnong Sunny Zhang

  • Justin Cidado

  • Lorraine Graham

  • Marianne Ashford

  • Barry Davies

Medical Centers

  • AstraZeneca, Waltham, MA

  • AstraZeneca, United Kingdom.

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Small cell lung cancer

  • B cell lymphomas

  • Solid malignancies

  • Lung Cancer

  • Lymphomas

  • B-cell acute lymphoblastic leukemia

  • Diffuse large B-cell lymphoma

Biomarkers

  • Myeloid Cell Leukemia 1

  • B-cell lymphoma 2

  • B-cell lymphoma-extra large

  • Bruton tyrosine kinase

Drug/Treatment

  • ACP-196

  • Venetoclax

  • Etoposide

  • Etoposide phosphate

  • Rituximab

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved